BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

The BRAF inhibitors vemurafenib, dabrafenib and encorafenib are used in the treatment of patients with BRAF-mutant melanoma. They selectively target BRAF kinase and thus interfere with the mitogen-activated protein kinase (MAPK) signalling pathway that regulates the proliferation and survival of mel...

Full description

Bibliographic Details
Main Authors: Ilaria Proietti, Nevena Skroza, Simone Michelini, Alessandra Mambrin, Veronica Balduzzi, Nicoletta Bernardini, Anna Marchesiello, Ersilia Tolino, Salvatore Volpe, Patrizia Maddalena, Marco Fraia, Giorgio Mangino, Giovanna Romeo, Concetta Potenza
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
BRAF-mutant melanoma
BRAF inhibitor
mechanism of action
melanoma
targeted therapy
tumour microenvironment
Online Access:https://www.mdpi.com/2072-6694/12/7/1823

Internet

https://www.mdpi.com/2072-6694/12/7/1823

Similar Items